Results 261 to 270 of about 25,581,606 (307)
Some of the next articles are maybe not open access.
Anthacyclines in non-small cell lung cancer
Lung Cancer, 2001The literature concerning the use of anthracyclines in the treatment of non-small cell lung cancer (NSCLC) is reviewed here. Overall, the activity of doxorubicin (DOXO) is unsatisfactory, whereas, the analogous epidoxorubicin (EPI) yields a 30% response rate (RR) when administered at intermediate-high doses.
P, Pronzato +4 more
openaire +2 more sources
Mobocertinib in non-small cell lung cancer
Drugs of Today, 2022Tyrosine kinase inhibitors (TKIs) have provided great benefit for patients with EGFR-mutant non-small cell lung cancer (NSCLC). While prior TKIs have demonstrated limited efficacy against exon 20 insertion mutations of EGFR (EGFR Ex20Ins), mobocertinib (TAK-788) is designed to specifically inhibit these Ex20Ins mutations. In a phase I/II clinical trial,
Shengwu, Liu, Kristen E, Lowder
openaire +2 more sources
Savolitinib for non-small cell lung cancer
Drugs of Today, 2023Savolitinib is a highly selective MET tyrosine kinase inhibitor. MET is involved in numerous cellular processes such as proliferation, differentiation and the formation of distant metastases. MET amplification and MET overexpression are quite common in many cancers, but MET exon 14 skipping alteration is most common in non-small cell lung cancer (NSCLC)
Magdalena, Zaborowska-Szmi +3 more
openaire +2 more sources
Nature Reviews Disease Primers
Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. The management of NSCLC has improved considerably, especially in the past 10 years. The systematic screening of populations at risk with low-dose CT, the implementation of novel surgical and ...
Lizza E. L. Hendriks +8 more
openaire +3 more sources
Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. The management of NSCLC has improved considerably, especially in the past 10 years. The systematic screening of populations at risk with low-dose CT, the implementation of novel surgical and ...
Lizza E. L. Hendriks +8 more
openaire +3 more sources
Ifosfamide in Non-Small Cell Lung Cancer
Oncology, 2003In recent years the role of chemotherapy in advanced non-small cell lung cancer (NSCLC) has been well established. Ifosfamide is an old drug still considered an effective cytostatic agent in the treatment of NSCLC. As a single agent, it has showed a response rate of 20–25%.
C, Boni, F, Zanelli
openaire +2 more sources
Pneumonectomy for non-small cell lung cancer
Surgery Today, 2012To assess the mortality, complications and major morbidity of pneumonectomy for non-small cell lung cancer (NSCLC) and to establish the importance of various prognostic factors.We reviewed retrospectively the hospital records of 71 consecutive patients who underwent pneumonectomy for NSCLC between 1992 and 2007 to evaluate the significance of risk ...
Yoshinobu, Ichiki +3 more
openaire +2 more sources
Vinorelbine for non-small cell lung cancer
Expert Opinion on Drug Safety, 2010Vinorelbine is a 'third-generation' vinca alkaloid approved for the treatment of NSCLC. The introduction of 'third-generation' drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with substantially similar results among the different drugs.
Maria Carmela, Piccirillo +7 more
openaire +2 more sources
Immunotherapy for non-small cell lung cancer
JAAPA, 2019ABSTRACT Immunotherapy is a new genre of treatment for patients with advanced cancer. Initially approved for use in metastatic melanoma, immunotherapy has found a significant place in treating non-small cell lung cancer (NSCLC). Clinical trials using several combinations of immunotherapy are underway to help to determine the best treatment ...
openaire +2 more sources
Gemcitabine in non-small cell lung cancer
Lung Cancer, 1995The pyrimidine antimetabolite gemcitabine is an analogue of cytosine arabinosid. Gemcitabine is well tolerated when given in doses of 1000-1250 mg/m2 weekly x 3 followed by 1 weeks rest, with mild myelosuppression as the major toxicity. In five studies, including a total of 250 patients with previously untreated non-small cell lung cancer (NSCLC ...
openaire +2 more sources
Chemoresistance in Non-Small Cell Lung Cancer
Current Medicinal Chemistry-Anti-Cancer Agents, 2005The treatment of advanced non-small-cell lung cancer (NSCLC is based on the combination of platin and one of the following agents: taxanes, gemcitabine, vinorelbine or irinotecan. There are no significant differences in efficacy among these combinations suggesting that the maximum efficacy has been reached.
Pascal, Sève, Charles, Dumontet
openaire +2 more sources

